Effects of personalized vitamin D3 on inflammation in colorectal cancer patients: a randomized trial.

Personalized vitamin D3 supplementation produced a 39.3% reduction in IL-6 levels compared to the placebo group in CRC patients.

• 95% CI: -54.9% to -18.2%; p = 0.001
• Trial included 126 patients (65 in the placebo group and 61 in the intervention group)
• IL-6 is described as a pro-inflammatory biomarker associated with poor prognosis in CRC
• The intervention consisted of a personalized loading dose followed by a maintenance dose of 2000 IU/day for 12 weeks

Reductions in IFN-γ and MMP-1 due to vitamin D3 supplementation were not statistically significant.

• IFN-γ reduction was -6.7% (p = 0.69)
• MMP-1 reduction was -5.4% (p = 0.23)
• Both biomarkers were measured at the end of the 12-week trial
• The same 126-patient cohort was used for all three biomarker analyses

The trial enrolled CRC patients who had undergone surgery in the past year and had low vitamin D status at baseline.

• Eligibility criterion for low vitamin D status was serum 25-hydroxyvitamin D levels < 60 nmol/L
• The study was a randomized double-blind, placebo-controlled trial conducted in Germany
• Patients were randomly assigned to either personalized vitamin D3 supplementation or placebo
• The intervention arm received a personalized loading dose followed by a maintenance dose of 2000 IU/day for 12 weeks
• The trial is described as 'ongoing' at the time of publication

Low vitamin D status and inflammation are associated with poor prognosis among colorectal cancer patients.

• This association motivated the trial's design targeting patients with serum 25-hydroxyvitamin D levels < 60 nmol/L
• IL-6 was selected as a primary inflammatory biomarker given its association with poor CRC prognosis
• IFN-γ and MMP-1 were also evaluated as secondary inflammatory biomarkers